ADAM2

ADAM2 (fertilin beta) is a sperm-surface ADAM-family protein whose principal characterized role is to assemble and chaperone the surface presentation of partner ADAM proteins on testicular germ cells and sperm (PMID:15194697, PMID:16014818). ADAM2 forms a heterodimeric fertilin complex with ADAM1 isoforms (ADAM1a, ADAM1b) in testicular germ cells (PMID:15194697, PMID:16407235), and this complex—together with the chaperone calnexin—is required for post-Golgi trafficking and surface stabilization of ADAM3 (cyritestin): in Adam2-null sperm ADAM3 is synthesized and traverses the Golgi but fails to reach the surface, and ADAM2/ADAM3 partition into a Triton X-100-insoluble, lipid-raft-like compartment that collapses without ADAM2 (PMID:16014818, PMID:17439939). The fertilin complex itself is dispensable for sperm-egg fusion, its primary function being surface presentation rather than the fusion step (PMID:16407235). Independently, the ADAM2 disintegrin domain mediates cell-cell adhesion: its QDECD loop, and specifically the terminal aspartate, is the critical determinant for sperm-egg binding (PMID:7593287, PMID:10713078), engaging egg-surface alpha4/alpha9- and ITGB1-containing integrins (PMID:11906941, PMID:21060781). This same disintegrin-loop activity drives neuroblast migration in the rostral migratory stream, where ADAM2 loss reduces migration speed and directionality and a disintegrin-loop peptide phenocopies the knockout (PMID:18380661). ADAM2 membrane behavior is modulated during sperm maturation and capacitation: cAMP increases lateral diffusion of the fertilin complex in mature but not testicular sperm (PMID:18667756), and cholesterol efflux during capacitation drives proteolytic processing of ADAM2 (PMID:19342015). In mouse lung cancer models ADAM2 acts as an oncogene that restrains interferon and TNF signaling, dampening tumor antigen presentation and immune checkpoint expression (PMID:37258521).

1. 1994 Medium

   Established that a defined region of the ADAM2 alpha-subunit can act as a fusogenic peptide, addressing whether fertilin contributes directly to membrane fusion machinery.

   Evidence Biophysical lipid-mixing and vesicle fusion assays with CD/FTIR on a synthetic PH-30 alpha peptide

   PMID:8161498

   Open questions at the time

   • Activity shown only for an isolated synthetic peptide, not full-length protein in cellular context
   • Does not establish fusogenic role in vivo during fertilization
2. 1995 Medium

   Identified the ADAM2 disintegrin domain as a participant in sperm-egg interaction, defining an adhesion function distinct from a canonical RGD integrin ligand.

   Evidence Peptide inhibition of sperm-egg binding/fusion using the QDE recognition sequence, with cDNA cloning

   PMID:7593287

   Open questions at the time

   • Peptide inhibition does not identify the egg receptor
   • Magnitude of inhibition leaves residual binding unexplained
3. 1997 Medium

   Refined the structural basis of fusogenic peptide activity by showing a Pro-Pro motif maintains the beta-structure required for fusion.

   Evidence CD spectroscopy and fusion assays on synthetic peptide analogs

   PMID:9266484

   Open questions at the time

   • Structure-activity established only at peptide level
   • No demonstration that this region adopts the same conformation in intact ADAM2
4. 2000 High

   Pinpointed the single critical residue (terminal aspartate of the QDECD loop) governing ADAM2 disintegrin adhesion, converting a domain-level model to residue-level resolution.

   Evidence Systematic site-directed mutagenesis of the disintegrin loop validated in two orthogonal sperm-egg/cell adhesion bioassays

   PMID:10713078

   Open questions at the time

   • Does not identify the binding partner engaged by the loop
   • Adhesion contribution to overall fertilization efficiency not quantified
5. 2002 Medium

   Identified candidate egg-surface receptors for the ADAM2 disintegrin domain, addressing what ADAM2 binds during gamete adhesion.

   Evidence MLDG/RGD peptide and anti-integrin/CD9 antibody blocking in two functional binding assays

   PMID:11906941

   Open questions at the time

   • Inhibitor-based identification without direct biochemical receptor isolation
   • Relative contributions of alpha4/alpha9 vs RGD-binding integrins not resolved
6. 2004 High

   Defined the fertilin complex (ADAM2-ADAM1a) and established that it is required for ADAM3 surface appearance, reframing ADAM2 as part of a surface-presentation pathway for other ADAMs.

   Evidence ADAM1a knockout mouse with surface protein analysis and co-immunoprecipitation

   PMID:15194697

   Open questions at the time

   • No direct interaction detected between the fertilin complex and ADAM3, leaving the linkage mechanism unclear
   • Does not localize the step at which ADAM3 is lost
7. 2005 High

   Localized ADAM2's role in ADAM3 biogenesis to post-Golgi trafficking and a lipid-raft-like compartment, distinguishing it from earlier secretory steps.

   Evidence Adam2 knockout mouse with endoglycosidase H resistance assay, Triton X-100 solubility fractionation, immunoblotting

   PMID:16014818

   Open questions at the time

   • Molecular identity of the post-Golgi sorting machinery not defined
   • How ADAM2 directs ADAM3 to the surface mechanistically unresolved
8. 2006 High

   Separated the fertilin complex's surface-presentation role from sperm-egg fusion, overturning the prior model that fertilin directly mediates fusion.

   Evidence ADAM1b knockout mouse with in vitro fertilization and zona-free fusion assays

   PMID:16407235

   Open questions at the time

   • Does not exclude redundant fusion mediators compensating
   • Fertility consequences attributable specifically to ADAM2 not isolated here
9. 2007 High

   Showed ADAM2 physically associates with and stabilizes ADAM3, with calnexin as a complex component, providing a biochemical basis for the trafficking dependence.

   Evidence Reciprocal co-immunoprecipitation, surface labeling, endoglycosidase H resistance, Adam2 knockout mouse

   PMID:17439939

   Open questions at the time

   • Reconciliation with earlier negative ADAM3 interaction result not fully explained
   • Stoichiometry and architecture of the ADAM2-ADAM3-calnexin assembly unknown
10. 2008 High

    Extended ADAM2 function beyond reproduction by demonstrating a disintegrin-domain-dependent role in neuroblast migration in the rostral migratory stream.

    Evidence ADAM2 knockout mouse with in vivo BrdU labeling, live slice imaging, explant migration assays, and disintegrin-loop peptide phenocopy

    PMID:18380661

    Open questions at the time

    • The cell-surface partner mediating neuroblast cell-cell interaction not identified
    • Whether ADAM3/fertilin complex participates in neural context unknown
11. 2008 Medium

    Demonstrated that fertilin complex lateral mobility is dynamically regulated by cAMP signaling, linking surface organization to capacitation-stage signaling.

    Evidence FRAP measurements with db-cAMP treatment in guinea pig sperm

    PMID:18667756

    Open questions at the time

    • Downstream effectors connecting cAMP to mobility not defined
    • Functional consequence of increased mobility for fertilization not measured
12. 2009 Medium

    Connected membrane lipid remodeling during capacitation to proteolytic maturation of ADAM2.

    Evidence Comparative capacitation assays in PCSK4-null vs wild-type sperm with cholesterol efflux manipulation and immunoblotting

    PMID:19342015

    Open questions at the time

    • Protease directly responsible for the 46-to-27 kDa processing not identified
    • Functional role of the processed form unknown
13. 2010 Medium

    Broadened the ADAM2 integrin receptor repertoire, identifying ITGB1-containing integrins and a novel ITGA9-ITGB7 heterodimer as binding partners.

    Evidence Antibody blocking and siRNA knockdown in cell adhesion assays across egg and RPMI 8866 cell systems

    PMID:21060781

    Open questions at the time

    • Binding-partner identification relies on inhibition rather than direct complex isolation
    • Physiological relevance of ITGA9-ITGB7 outside the cell line untested
14. 2016 Low

    Highlighted species divergence in ADAM2 biology, showing human ADAM2 is testis-expressed but absent from sperm unlike mouse and monkey.

    Evidence Western blotting with species-specific antibodies and co-immunoprecipitation for chaperone association

    PMID:27341348

    Open questions at the time

    • Single immunoblot/pulldown approach without functional follow-up
    • Cytoplasmic-domain role in differential ADAM association only suggested, not demonstrated
15. 2023 Medium

    Revealed an unexpected oncogenic, immunomodulatory role for ADAM2 in restraining cytokine signaling, antigen presentation, and checkpoint expression in tumors.

    Evidence In vivo CRISPR/Cas9 screen with loss- and gain-of-function experiments and cytokine/antigen-presentation readouts in mouse lung cancer models

    PMID:37258521

    Open questions at the time

    • Molecular mechanism by which ADAM2 restrains interferon/TNF signaling not defined
    • Whether the disintegrin or other domains mediate this effect unknown
    • Relevance to human cancer untested

• How ADAM2's disintegrin-adhesion function, its fertilin-complex chaperone/trafficking role, and its tumor immunomodulatory activity mechanistically interrelate—and whether they share a common molecular activity—remains unresolved.
• No structural model of the fertilin complex or its ADAM3 sorting platform
• Direct molecular mechanism of the cancer immune phenotype undefined
• Human ADAM2 function not characterized given its absence from sperm